Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 38 analyst ratings
Buy
Strong Buy 32%
Buy 45%
Hold 16%
Sell 0%
Strong Sell 8%

Bulls say

Insulet has demonstrated strong financial performance, with global Omnipod sales up 26% year-over-year on an underlying basis in Q4'24, reflecting robust demand for its innovative insulin delivery system. The company achieved total sales of $2.07 billion in 2024, representing a 22% increase year-over-year, alongside an earnings per share (EPS) of $3.24, exceeding market expectations. Additionally, Insulet's significant milestone of reaching over 500,000 active customers and stable utilization and retention rates underscores the ongoing growth momentum and competitive positioning of the Omnipod system across various markets.

Bears say

Insulet's financial outlook is negatively affected by a notable decline in operating and adjusted EBITDA margins, with decreases of 240 basis points and 160 basis points year-over-year, respectively, indicating potential operational inefficiencies. The company also faces significant revenue challenges, particularly within its Drug Delivery segment, which is expected to see declines ranging from 45-55% year-over-year, alongside a cautious sales growth guidance of 16-20% for 2025, particularly impacted by reliance on third-party distributors. Furthermore, if Insulet fails to effectively grow its customer base or experiences intensified competition in diabetes management solutions, the risk of further revenue decline becomes increasingly pronounced.

Insulet (PODD) has been analyzed by 38 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 45% recommend Buy, 16% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 38 analysts, Insulet (PODD) has a Buy consensus rating as of Jul 19, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $216.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $216.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.